Results 241 to 250 of about 547,306 (324)
Swelling, Serosal Adhesion, Protein Adsorption, and Biocompatibility of Pectin-TEOS Gels. [PDF]
Paderin N, Sokolova A, Popov S.
europepmc +1 more source
CX3CL1 in Early Detection of Alzheimer's Disease: Plasma Dynamics Across Age and Disease Stages
ABSTRACT Backgrounds Alzheimer's disease (AD) is characterized by amyloid‐beta plaques, tau tangles, and neuroinflammation. C‐X3‐C motif chemokine ligand 1 (CX3CL1, also known as fractalkine), a neuroimmune chemokine implicated in AD pathogenesis, shows inconsistent alterations in plasma/serum across studies.
Ling Wang +6 more
wiley +1 more source
Dual roles of complement in ulcerative colitis: insights from clinical studies and animal research. [PDF]
Qin Z, Wang R, Zhang Y.
europepmc +1 more source
Objective Lupus low disease activity state (LLDAS) is a validated treatment target in systemic lupus erythematosus (SLE), but limited studies have explored the role of LLDAS in lupus nephritis (LN). This study aims to investigate the frequency and predictors of LLDAS attainment and its benefit on LN relapse and renal function preservation in patients ...
Chak Kwan Cheung +6 more
wiley +1 more source
Complement pathway dysregulation and astrocyte alterations in Down syndrome: evidence from postmortem brain tissue and iPSC-derived astrocytes. [PDF]
Teles E Silva AL +7 more
europepmc +1 more source
WCN24-2459 SARS-COV2 PROTEIN IN RENAL TISSUE ENHANCED ACTIVATION OF COMPLEMENT SYSTEM IN MN PATIENTS WITH COVID-19 INFECTION [PDF]
Hong Cheng +7 more
openalex +1 more source
Objective Although treat‐to‐target urate‐lowering therapy (ULT) is endorsed as best practice in gout management, limited data exist on its impact on health‐related quality of life (HRQoL). We assessed the impact of treat‐to‐target ULT on HRQoL among participants receiving protocolized gout care, identifying factors associated with HRQoL and HRQoL ...
Austin Barry +16 more
wiley +1 more source
Objective A leading cause of death among scleroderma (SSc) patients, interstitial lung disease (ILD) remains challenging to prognosticate. The discovery of biomarkers that accurately determine which patients would benefit from close monitoring and aggressive therapy would be an essential clinical tool.
Cristina M Padilla +13 more
wiley +1 more source

